Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
A voluminous mass as an initial clinical symptom of multiple myeloma: A case report.

Experimental and therapeutic medicine

Sgherza N, Iacobazzi A, Cramarossa A, DE Tullio G, Guarini A.
PMID: 26640537
Exp Ther Med. 2015 Nov;10(5):1689-1691. doi: 10.3892/etm.2015.2720. Epub 2015 Sep 01.

Extramedullary multiple myeloma (EMM) is a type of multiple myeloma (MM) that is defined by the presence of extraskeletal (soft tissue or visceral) clonal plasma cell infiltrates, which may be present at the time of initial diagnosis or at...

Cite
Sgherza N, Iacobazzi A, Cramarossa A, et al. A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Exp Ther Med. 2015;10(5):1689-1691doi: 10.3892/etm.2015.2720.
Sgherza, N., Iacobazzi, A., Cramarossa, A., DE Tullio, G., & Guarini, A. (2015). A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Experimental and therapeutic medicine, 10(5), 1689-1691. https://doi.org/10.3892/etm.2015.2720
Sgherza, Nicola, et al. "A voluminous mass as an initial clinical symptom of multiple myeloma: A case report." Experimental and therapeutic medicine vol. 10,5 (2015): 1689-1691. doi: https://doi.org/10.3892/etm.2015.2720
Sgherza N, Iacobazzi A, Cramarossa A, DE Tullio G, Guarini A. A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. Exp Ther Med. 2015 Nov;10(5):1689-1691. doi: 10.3892/etm.2015.2720. Epub 2015 Sep 01. PMID: 26640537; PMCID: PMC4665678.
Copy Download .nbib Format: NLM
Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report.

Oncology letters

Strippoli S, Traversa M, Cramarossa A, Popescu O, Lorusso V, Guida M.
PMID: 26137107
Oncol Lett. 2015 Jun;9(6):2567-2571. doi: 10.3892/ol.2015.3111. Epub 2015 Apr 14.

Extraskeletal osteosarcomas (EOSs) are rare variants of primary osteosarcoma of the bone, and are defined as sarcomas located in the soft tissues and characterized by osteoid production. EOS exhibits distinctive demographic, imaging and prognostic features compared with osteosarcoma of...

Cite
Strippoli S, Traversa M, Cramarossa A, et al. Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncol Lett. 2015;9(6):2567-2571doi: 10.3892/ol.2015.3111.
Strippoli, S., Traversa, M., Cramarossa, A., Popescu, O., Lorusso, V., & Guida, M. (2015). Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncology letters, 9(6), 2567-2571. https://doi.org/10.3892/ol.2015.3111
Strippoli, Sabino, et al. "Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report." Oncology letters vol. 9,6 (2015): 2567-2571. doi: https://doi.org/10.3892/ol.2015.3111
Strippoli S, Traversa M, Cramarossa A, Popescu O, Lorusso V, Guida M. Long-term response of gemcitabine plus docetaxel chemotherapy regimen for extraskeletal osteosarcoma: A case report. Oncol Lett. 2015 Jun;9(6):2567-2571. doi: 10.3892/ol.2015.3111. Epub 2015 Apr 14. PMID: 26137107; PMCID: PMC4473531.
Copy Download .nbib Format: NLM
Symptom Clusters Using the Edmonton Symptom Assessment System in Patients With Bone Metastases: A Reanalysis Comparing Different Statistical Methods.

World journal of oncology

Khan L, Cramarossa G, Chen E, Nguyen J, Zhang L, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Culleton S, Chow E.
PMID: 29147274
World J Oncol. 2012 Feb;3(1):23-32. doi: 10.4021/wjon403w. Epub 2012 Feb 19.

BACKGROUND: To determine whether symptom clusters in patients with bone metastases vary when extracted using three different statistical methods. To compare the temporal composition of symptom clusters in responders versus non-responders to palliative radiation treatment.METHODS: A previous dataset of...

Cite
Khan L, Cramarossa G, Chen E, et al. Symptom Clusters Using the Edmonton Symptom Assessment System in Patients With Bone Metastases: A Reanalysis Comparing Different Statistical Methods. World J Oncol. 2012;3(1):23-32doi: 10.4021/wjon403w.
Khan, L., Cramarossa, G., Chen, E., Nguyen, J., Zhang, L., Tsao, M., Danjoux, C., Barnes, E., Sahgal, A., Holden, L., Jon, F., Culleton, S., & Chow, E. (2012). Symptom Clusters Using the Edmonton Symptom Assessment System in Patients With Bone Metastases: A Reanalysis Comparing Different Statistical Methods. World journal of oncology, 3(1), 23-32. https://doi.org/10.4021/wjon403w
Khan, Luluel, et al. "Symptom Clusters Using the Edmonton Symptom Assessment System in Patients With Bone Metastases: A Reanalysis Comparing Different Statistical Methods." World journal of oncology vol. 3,1 (2012): 23-32. doi: https://doi.org/10.4021/wjon403w
Khan L, Cramarossa G, Chen E, Nguyen J, Zhang L, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Culleton S, Chow E. Symptom Clusters Using the Edmonton Symptom Assessment System in Patients With Bone Metastases: A Reanalysis Comparing Different Statistical Methods. World J Oncol. 2012 Feb;3(1):23-32. doi: 10.4021/wjon403w. Epub 2012 Feb 19. PMID: 29147274; PMCID: PMC5649832.
Copy Download .nbib Format: NLM
Symptom Clusters in Cancer Patients With Bone Metastases: Subanalysis of Patients Reporting Exclusively Non-zero ESAS Scores.

World journal of oncology

Cramarossa G, Chen E, Khan L, Zhang L, Nguyen J, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Dennis K, Chow E.
PMID: 29147263
World J Oncol. 2011 Dec;2(6):281-288. doi: 10.4021/wjon386w. Epub 2011 Dec 19.

BACKGROUND: To identify symptom clusters in a subgroup of patients reporting exclusively non-zero Edmonton Symptom Assessment System (ESAS) scores at baseline, and to compare clusters with those identified in the total patient population. Secondary objective was to determine whether...

Cite
Cramarossa G, Chen E, Khan L, et al. Symptom Clusters in Cancer Patients With Bone Metastases: Subanalysis of Patients Reporting Exclusively Non-zero ESAS Scores. World J Oncol. 2011;2(6):281-288doi: 10.4021/wjon386w.
Cramarossa, G., Chen, E., Khan, L., Zhang, L., Nguyen, J., Tsao, M., Danjoux, C., Barnes, E., Sahgal, A., Holden, L., Jon, F., Dennis, K., & Chow, E. (2011). Symptom Clusters in Cancer Patients With Bone Metastases: Subanalysis of Patients Reporting Exclusively Non-zero ESAS Scores. World journal of oncology, 2(6), 281-288. https://doi.org/10.4021/wjon386w
Cramarossa, Gemma, et al. "Symptom Clusters in Cancer Patients With Bone Metastases: Subanalysis of Patients Reporting Exclusively Non-zero ESAS Scores." World journal of oncology vol. 2,6 (2011): 281-288. doi: https://doi.org/10.4021/wjon386w
Cramarossa G, Chen E, Khan L, Zhang L, Nguyen J, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Dennis K, Chow E. Symptom Clusters in Cancer Patients With Bone Metastases: Subanalysis of Patients Reporting Exclusively Non-zero ESAS Scores. World J Oncol. 2011 Dec;2(6):281-288. doi: 10.4021/wjon386w. Epub 2011 Dec 19. PMID: 29147263; PMCID: PMC5649712.
Copy Download .nbib Format: NLM
(Perylene)(3)[Bi(4)Br(12)]: A New Arene pi-Complex Containing the [Bi(4)Br(12)] Unit.

Inorganic chemistry

Battaglia LP, Bellitto C, Cramarossa MR, Vezzosi IM.
PMID: 11666441
Inorg Chem. 1996 Apr 10;35(8):2390-2392. doi: 10.1021/ic950986r.

No abstract available.

Cite
Battaglia LP, Bellitto C, Cramarossa MR, et al. (Perylene)(3)[Bi(4)Br(12)]: A New Arene pi-Complex Containing the [Bi(4)Br(12)] Unit. Inorg Chem. 1996;35(8):2390-2392doi: 10.1021/ic950986r.
Battaglia, L. P., Bellitto, C., Cramarossa, M. R., & Vezzosi, I. M. (1996). (Perylene)(3)[Bi(4)Br(12)]: A New Arene pi-Complex Containing the [Bi(4)Br(12)] Unit. Inorganic chemistry, 35(8), 2390-2392. https://doi.org/10.1021/ic950986r
Battaglia, Luigi Pietro, et al. "(Perylene)(3)[Bi(4)Br(12)]: A New Arene pi-Complex Containing the [Bi(4)Br(12)] Unit." Inorganic chemistry vol. 35,8 (1996): 2390-2392. doi: https://doi.org/10.1021/ic950986r
Battaglia LP, Bellitto C, Cramarossa MR, Vezzosi IM. (Perylene)(3)[Bi(4)Br(12)]: A New Arene pi-Complex Containing the [Bi(4)Br(12)] Unit. Inorg Chem. 1996 Apr 10;35(8):2390-2392. doi: 10.1021/ic950986r. PMID: 11666441.
Copy Download .nbib Format: NLM
Larger Cyclophanes: Synthesis and Structural Characterization of [2.2.2.2]Paracyclophane Compounds with SbBr(3) and BiBr(3).

Inorganic chemistry

Ferrari MB, Cramarossa MR, Iarossi D, Pelosi G.
PMID: 11670720
Inorg Chem. 1998 Oct 19;37(21):5681-5685. doi: 10.1021/ic971314z.

No abstract available.

Cite
Ferrari MB, Cramarossa MR, Iarossi D, et al. Larger Cyclophanes: Synthesis and Structural Characterization of [2.2.2.2]Paracyclophane Compounds with SbBr(3) and BiBr(3). Inorg Chem. 1998;37(21):5681-5685doi: 10.1021/ic971314z.
Ferrari, M. B., Cramarossa, M. R., Iarossi, D., & Pelosi, G. (1998). Larger Cyclophanes: Synthesis and Structural Characterization of [2.2.2.2]Paracyclophane Compounds with SbBr(3) and BiBr(3). Inorganic chemistry, 37(21), 5681-5685. https://doi.org/10.1021/ic971314z
Ferrari, Marisa Belicchi, et al. "Larger Cyclophanes: Synthesis and Structural Characterization of [2.2.2.2]Paracyclophane Compounds with SbBr(3) and BiBr(3)." Inorganic chemistry vol. 37,21 (1998): 5681-5685. doi: https://doi.org/10.1021/ic971314z
Ferrari MB, Cramarossa MR, Iarossi D, Pelosi G. Larger Cyclophanes: Synthesis and Structural Characterization of [2.2.2.2]Paracyclophane Compounds with SbBr(3) and BiBr(3). Inorg Chem. 1998 Oct 19;37(21):5681-5685. doi: 10.1021/ic971314z. PMID: 11670720.
Copy Download .nbib Format: NLM
Study of .

Biotechnology for biofuels

Filippucci S, Tasselli G, Scardua A, Di Mauro S, Cramarossa MR, Perini D, Turchetti B, Onofri A, Forti L, Buzzini P.
PMID: 27933101
Biotechnol Biofuels. 2016 Nov 28;9:259. doi: 10.1186/s13068-016-0672-1. eCollection 2016.

CONCLUSIONS: This study provides some meaningful information about the lipogenic ability of some yeast species. Variable lipid yields and fatty acid profiles were observed in dependence of both temperature and different carbon sources.

Cite
Filippucci S, Tasselli G, Scardua A, et al. Study of . Biotechnol Biofuels. 2016;9:259doi: 10.1186/s13068-016-0672-1.
Filippucci, S., Tasselli, G., Scardua, A., Di Mauro, S., Cramarossa, M. R., Perini, D., Turchetti, B., Onofri, A., Forti, L., & Buzzini, P. (2016). Study of . Biotechnology for biofuels, 9259. https://doi.org/10.1186/s13068-016-0672-1
Filippucci, Sara, et al. "Study of ." Biotechnology for biofuels vol. 9 (2016): 259. doi: https://doi.org/10.1186/s13068-016-0672-1
Filippucci S, Tasselli G, Scardua A, Di Mauro S, Cramarossa MR, Perini D, Turchetti B, Onofri A, Forti L, Buzzini P. Study of . Biotechnol Biofuels. 2016 Nov 28;9:259. doi: 10.1186/s13068-016-0672-1. eCollection 2016. PMID: 27933101; PMCID: PMC5126845.
Copy Download .nbib Format: NLM
Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease.

International journal of oncology

Lorusso V, Timurian A, Brandi M, Pellecchia A, Cramarossa A, Marzullo F, Delena M.
PMID: 21544411
Int J Oncol. 1996 Apr;8(4):669-74. doi: 10.3892/ijo.8.4.669.

The aim of the study was to verify the possibility of treating patients with poor prognosis early-intermediate Hodgkin's disease with a combined modality therapy consisting of three cycles of ABVD followed by extended field irradiation (EFRT). No patient had...

Cite
Lorusso V, Timurian A, Brandi M, et al. Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease. Int J Oncol. 1996;8(4):669-74doi: 10.3892/ijo.8.4.669.
Lorusso, V., Timurian, A., Brandi, M., Pellecchia, A., Cramarossa, A., Marzullo, F., & Delena, M. (1996). Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease. International journal of oncology, 8(4), 669-74. https://doi.org/10.3892/ijo.8.4.669
Lorusso, V, et al. "Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease." International journal of oncology vol. 8,4 (1996): 669-74. doi: https://doi.org/10.3892/ijo.8.4.669
Lorusso V, Timurian A, Brandi M, Pellecchia A, Cramarossa A, Marzullo F, Delena M. Three cycles of ABDV plus extended field radiotherapy in patients with poor prognosis early-intermediate stage Hodgkin's disease. Int J Oncol. 1996 Apr;8(4):669-74. doi: 10.3892/ijo.8.4.669. PMID: 21544411.
Copy Download .nbib Format: NLM
Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer.

Expert review of pharmacoeconomics & outcomes research

Lien K, Zeng L, Nguyen J, Cramarossa G, Culleton S, Caissie A, Lutz S, Chow E.
PMID: 21958099
Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):541-7. doi: 10.1586/erp.11.64.

Shorter quality-of-life (QoL) assessments are beneficial for palliative patients as they reduce burden associated with completing personal, and at times stressful, questionnaires. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 15 Palliative (QLQ-C15-PAL)...

Cite
Lien K, Zeng L, Nguyen J, et al. Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. Expert Rev Pharmacoecon Outcomes Res. 2011;11(5):541-7doi: 10.1586/erp.11.64.
Lien, K., Zeng, L., Nguyen, J., Cramarossa, G., Culleton, S., Caissie, A., Lutz, S., & Chow, E. (2011). Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. Expert review of pharmacoeconomics & outcomes research, 11(5), 541-7. https://doi.org/10.1586/erp.11.64
Lien, Karen, et al. "Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer." Expert review of pharmacoeconomics & outcomes research vol. 11,5 (2011): 541-7. doi: https://doi.org/10.1586/erp.11.64
Lien K, Zeng L, Nguyen J, Cramarossa G, Culleton S, Caissie A, Lutz S, Chow E. Comparison of the EORTC QLQ-C15-PAL and the FACIT-Pal for assessment of quality of life in patients with advanced cancer. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct;11(5):541-7. doi: 10.1586/erp.11.64. PMID: 21958099.
Copy Download .nbib Format: NLM
Poor Accrual in Palliative Research Studies: An Update From the Rapid Response Radiotherapy Program.

World journal of oncology

Lien K, Zeng L, Bradley N, Culleton S, Popovic M, Di Giovanni J, Jamani R, Cramarossa G, Nguyen J, Koo K, Jon F, Chow E.
PMID: 29147251
World J Oncol. 2011 Oct;2(5):217-224. doi: 10.4021/wjon357w. Epub 2011 Oct 28.

BACKGROUND: In June 2003, the Rapid Response Radiotherapy Program (RRRP) implemented changes to recruitment strategies in attempts to increase patient accrual to research studies. Such modifications included the use of a dedicated research assistant to screen for and identify...

Cite
Lien K, Zeng L, Bradley N, et al. Poor Accrual in Palliative Research Studies: An Update From the Rapid Response Radiotherapy Program. World J Oncol. 2011;2(5):217-224doi: 10.4021/wjon357w.
Lien, K., Zeng, L., Bradley, N., Culleton, S., Popovic, M., Di Giovanni, J., Jamani, R., Cramarossa, G., Nguyen, J., Koo, K., Jon, F., & Chow, E. (2011). Poor Accrual in Palliative Research Studies: An Update From the Rapid Response Radiotherapy Program. World journal of oncology, 2(5), 217-224. https://doi.org/10.4021/wjon357w
Lien, Karen, et al. "Poor Accrual in Palliative Research Studies: An Update From the Rapid Response Radiotherapy Program." World journal of oncology vol. 2,5 (2011): 217-224. doi: https://doi.org/10.4021/wjon357w
Lien K, Zeng L, Bradley N, Culleton S, Popovic M, Di Giovanni J, Jamani R, Cramarossa G, Nguyen J, Koo K, Jon F, Chow E. Poor Accrual in Palliative Research Studies: An Update From the Rapid Response Radiotherapy Program. World J Oncol. 2011 Oct;2(5):217-224. doi: 10.4021/wjon357w. Epub 2011 Oct 28. PMID: 29147251; PMCID: PMC5649682.
Copy Download .nbib Format: NLM
Symptom Clusters in Patients With Bone Metastases: A Sub-Analysis of Patients Reporting Exclusively Non-Zero BPI Scores.

World journal of oncology

Cramarossa G, Nguyen J, Zhang L, Chen E, Khan L, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Chow E.
PMID: 29147272
World J Oncol. 2012 Feb;3(1):8-15. doi: 10.4021/wjon394w. Epub 2012 Feb 19.

BACKGROUND: The use of different statistical methods and inclusion criteria when deriving symptom clusters in cancer patients are contributing factors in cluster inconsistencies across studies. Primary objective was to extract symptom clusters in a subgroup of patients reporting non-zero...

Cite
Cramarossa G, Nguyen J, Zhang L, et al. Symptom Clusters in Patients With Bone Metastases: A Sub-Analysis of Patients Reporting Exclusively Non-Zero BPI Scores. World J Oncol. 2012;3(1):8-15doi: 10.4021/wjon394w.
Cramarossa, G., Nguyen, J., Zhang, L., Chen, E., Khan, L., Tsao, M., Danjoux, C., Barnes, E., Sahgal, A., Holden, L., Jon, F., & Chow, E. (2012). Symptom Clusters in Patients With Bone Metastases: A Sub-Analysis of Patients Reporting Exclusively Non-Zero BPI Scores. World journal of oncology, 3(1), 8-15. https://doi.org/10.4021/wjon394w
Cramarossa, Gemma, et al. "Symptom Clusters in Patients With Bone Metastases: A Sub-Analysis of Patients Reporting Exclusively Non-Zero BPI Scores." World journal of oncology vol. 3,1 (2012): 8-15. doi: https://doi.org/10.4021/wjon394w
Cramarossa G, Nguyen J, Zhang L, Chen E, Khan L, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Chow E. Symptom Clusters in Patients With Bone Metastases: A Sub-Analysis of Patients Reporting Exclusively Non-Zero BPI Scores. World J Oncol. 2012 Feb;3(1):8-15. doi: 10.4021/wjon394w. Epub 2012 Feb 19. PMID: 29147272; PMCID: PMC5649830.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries